Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in two upcoming virtual investor conferences. Goldman Sachs Cell Therapy DayMonday, April 6, 20209:30 AM PT/12:30 PM ET Canaccord Genuity Horizons in Oncology ConferenceWednesday, April 8, 20209:45 AM PT/12:45 PM ET Webcasts will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days. About Allogene TherapeuticsAllogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by
Show less
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) ReportGlobeNewswire
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) is now covered by analysts at Sanford C. Bernstein. They set a "market perform" rating on the stock.MarketBeat
- Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual MeetingGlobeNewswire
- Allogene: ALLO-715 Phase 1 Results And ALLO-213 Preclinical Data Is Promising [Seeking Alpha]Seeking Alpha
ALLO
Earnings
- 2/28/23 - Beat
ALLO
Sec Filings
- 3/24/23 - Form 4
- 3/24/23 - Form 4
- 3/24/23 - Form 4
- ALLO's page on the SEC website